| 1.8 -0.03 (-1.64%) | 11-29 10:11 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.88 | 1-year : | 3.36 |
| Resists | First : | 2.47 | Second : | 2.88 |
| Pivot price | 1.68  |
|||
| Supports | First : | 1.33 | Second : | 0.62 |
| MAs | MA(5) : | 1.92 |
MA(20) : | 1.56 |
| MA(100) : | 1.71 |
MA(250) : | 6.23 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 69.2 |
D(3) : | 72.3 |
| RSI | RSI(14): 55.7 |
|||
| 52-week | High : | 18.6 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ INVO ] has closed below upper band by 43.2%. Bollinger Bands are 19.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.04 - 2.05 | 2.05 - 2.06 |
| Low: | 1.68 - 1.69 | 1.69 - 1.7 |
| Close: | 1.81 - 1.83 | 1.83 - 1.85 |
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.
Tue, 28 Nov 2023
Do Traders Think Invo Bioscience Inc (INVO) Can Keep Climbing Tuesday? - InvestorsObserver
Tue, 28 Nov 2023
INVO Bioscience Regains Compliance with Nasdaq Minimum ... - Yahoo Finance
Tue, 21 Nov 2023
Thinking about buying stock in DraftKings, elf Beauty, IONQ ... - PR Newswire
Fri, 17 Nov 2023
Invo Bioscience Inc (INVO) Down 2.09% in Premarket Trading - InvestorsObserver
Wed, 15 Nov 2023
Healthcare Stocks Making Moves Wednesday: KNTE, SPRC, SLDB, XAIR, MAIA, AYTU, TIVC, INVO - InvestorsObserver
Tue, 14 Nov 2023
Healthcare Stocks on the Move Tuesday: BCDA, THRX, PXMD, INVO, HROW, XAIR, BTAI, KRRO - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 2.22e+006 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 123 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.9e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -91 % |
| Return on Assets (ttm) | -41.3 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 1.92e+006 % |
| Gross Profit (p.s.) | 241.76 |
| Sales Per Share | 46.96 |
| EBITDA (p.s.) | 411746 |
| Qtrly Earnings Growth | -10.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.03 |
| Price to Cash Flow | 15.61 |
| Dividend | 0 |
| Forward Dividend | 289010 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|